Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness a...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Hironori Yamamoto
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI AG 2025-02-01
Cyfres:Metabolites
Pynciau:
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
pemafibrate
dyslipidemia
metabolic dysfunction-associated steatotic liver disease
Mynediad Ar-lein:https://www.mdpi.com/2218-1989/15/2/100

Rhyngrwyd

https://www.mdpi.com/2218-1989/15/2/100

Eitemau Tebyg